| 2025-12-20 |
复牌提示：
2025-12-19 19:50:00 停牌，复牌日期 2025-12-22 09:00:00
|
| 2025-12-18 |
详情>>
股本变动：
变动后总股本576.90万股
变动原因 ▼▲
- 原因：
- a reverse stock split of the Company's common stock at a ratio of one (1) share for every ten (10) shares of common stock outstanding
|
| 2025-12-18 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2025-11-19 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.19美元,归母净利润-734.5万美元,同比去年增长61.35%
|
| 2025-10-31 |
股东大会：
将于2025-11-24召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation to clarify that the Company may acquire, hold, exchange, and manage digital assets, blockchain-based instruments, as part of a digital asset and corporate crypto treasury management strategy (the “Digital Asset Charter Amendment”);
2.To approve an amendment to the Company’s Certificate of Incorporation to create a new class of “Digital Treasury Shares” (or such other designation as the Board may determine), that may represent fractional or tokenized interests in digital or blockchain-based assets (the “Digital Treasury Shares Proposal”);
3.To authorize the potential issuance of digital tokens or tokenized securities representing up to 4.99% of the Company’s outstanding equity, for use in financing, compensation, strategic partnerships, or treasury operations in furtherance of the Company’s digital asset strategy (the “Tokenized Issuance”);
4.To approve an amendment to the Company’s Certificate of Incorporation authorizing the Board, without further stockholder approval, to effect one or more reverse or forward stock splits of the Company’s Common Stock, to set the timing of a stock split, or to refrain from taking such action, at a ratio to be determined by the Board (but not less than 1-for-2 and not greater than 1-for-10), to maintain compliance with Nasdaq Listing Rule 5810(c)(A) and to support the Company’s strategic objectives, including its exploration of digital asset initiatives, and, at the discretion of the Board of Directors, a corresponding reduction in the number of authorized shares of common stock (the “Split Authorization”);
5.To approve a conditional amendment to increase authorized Common Stock in order to satisfy outstanding contractual or derivative-security obligations (the “Increase Proposal”);
6.To approve the adjournment of the special meeting, if necessary or appropriate, to solicit additional proxies (the “Adjournment Proposal”);
7.To transact such other business as may properly come before the meeting.
|
| 2025-08-15 |
股东大会：
将于2025-09-09召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), (i) an amendment to the Company’s Amended and Restated 2022 Equity Compensation Plan to increase the number of shares authorized for issuance thereunder by 3,000,000 shares, and (ii) the adoption of the Company’s Amended and Restated 2025 Equity Compensation Plan, as approved by the Board of Directors, to supersede the 2022 Plan, contingent on the approval of Proposal 3. (Proposal 1);
2.To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), (i) an amendment to the Company’s Amended and Restated 2022 Directors’ Equity Compensation Plan to increase the number of shares authorized for issuance thereunder by 500,000 shares, and (ii) the adoption of the Company’s Amended and Restated 2025 Directors’ Equity Compensation Plan, as approved by the Board of Directors, to supersede the 2022 Directors’ Plan, contingent on the approval of Proposal 3. (Proposal 2);
3.To approve an amendment to Article FOURTH of the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 50,000,000 to 1,000,000,000 shares, as recommended by the Board of Directors to transform the structure of the Company to have the flexibility to attract investors and execute on the optimal crypto treasury strategy. (Proposal 3);
4.To approve, on a non-binding, advisory basis, the Board of Directors’ adoption of a share repurchase program authorizing the Company, in its discretion, to repurchase up to $15 million of its outstanding common stock from time to time in the open market or through privately negotiated transactions, subject to applicable law and the Company’s financial condition. (Proposal 4);
5.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance by the Company of up to 226,310,704 shares of common stock (and/or securities convertible into or exercisable for common stock) in connection with the private placement entered into on July 22, 2025, including any additional $3 million permitted on substantially similar terms, which may result in the issuance of more than 20% of the Company’s outstanding shares as of the date of issuance, at a price that may be less than the greater of book value or market value, as determined under Nasdaq rules. The terms of the private placement contain a four-month waiting period before the notes become convertible and the Company has the right to prepay at any time without penalty, including prior to the time when the notes become convertible. (Proposal 5);
6.To approve an amendment to the Company’s By-Laws to add the address of its principal executive offices: 626 RXR Plaza, 6th Floor, Uniondale, NY 11556 (this proposal is considered a routine matter for which brokers may exercise discretionary voting authority). (Proposal 6);
7.To transact such other business as may properly come before the Special Meeting and any adjournments or postponements thereof.
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.01美元,归母净利润-50.6万美元,同比去年增长95.93%
|
| 2025-08-13 |
财报披露：
美东时间 2025-08-13 盘前发布财报
|
| 2025-06-23 |
股东大会：
将于2025-07-18召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Fruci & Associates II, PLLC as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To hold an advisory vote to approve executive compensation (the “Say-on-Pay Vote”);
4.To hold an advisory vote on the frequency of future Say-on-Pay Votes (the “Say-on-Frequency Vote”);
5.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
6.For Proposal 1 (the election of directors), you may vote “FOR ALL NOMINEES,” “WITHHOLD AUTHORITY FOR ALL NOMINEES,” or “FOR ALL EXCEPT” one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors and will not affect the results of that vote. For Proposal 2 (the ratification of our independent registered public accounting firm for the fiscal year ending December 31, 2024), you may vote “FOR”, “AGAINST” or “ABSTAIN.” For abstentions, see “What happens if I abstain from voting” below. For Proposal 3 (the Say-on-Pay Vote), you may vote “FOR”, “AGAINST” or “ABSTAIN.” For abstentions, see “What happens if I abstain from voting” below. For Proposal 4 (the Say-on-Frequency Vote), you may vote to have future Say-on-Pay Votes held every year, every two years or every three years (the current frequency) or you may abstain from this vote. If you specify a voting choice, the shares will be voted in accordance with that choice. If you vote your shares, but do not indicate your voting preferences, the Named Proxies will vote your shares in accordance with the recommendations of the Board. If you are a beneficial owner and you have not provided voting instructions to your bank, broker or nominee, your bank, broker or nominee may exercise discretion to vote your shares only with respect to the ratification of our independent registered public accounting firm. Your bank, broker or nominee does not have discretionary authority to vote your shares in the election of directors, resulting in “broker-non-votes” with respect to these proposals. See “What is a broker non-vote” for more information.
|
| 2025-05-20 |
详情>>
业绩披露：
2025年一季报每股收益0.11美元,归母净利润396.60万美元,同比去年增长163.30%
|
| 2025-04-01 |
详情>>
业绩披露：
2024年年报每股收益-2.61美元,归母净利润-5336.4万美元,同比去年增长-217.98%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.02美元,归母净利润-1900.5万美元,同比去年增长-136.65%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.67美元,归母净利润-1241.8万美元,同比去年增长-329.69%
|
| 2024-05-15 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the 2025 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Morison Cogen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.35美元,归母净利润-626.5万美元,同比去年增长-1239.09%
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-0.98美元,归母净利润-1678.2万美元,同比去年增长-190.9%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.47美元,归母净利润-803.1万美元,同比去年增长-138.41%
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-0.17美元,归母净利润-289万美元,同比去年增长-114.49%
|
| 2023-04-27 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Morison Cogen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To consider and act upon a proposal to approve the Amended and Restated 2022 Equity Compensation Plan;
4.To consider and act upon a proposal to approve the Amended and Restated 2022 Directors’ Equity Compensation Plan;
5.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2023-04-05 |
详情>>
内部人交易：
Karkus Ted William股份减少50000.00股
|
| 2022-04-13 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Friedman LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To consider and act upon a proposal to approve the 2022 Equity Compensation Plan;
4.To consider and act upon a proposal to approve the 2022 Directors’ Equity Compensation Plan;
5.To hold an advisory vote to approve the compensation of our named executive officers;
6.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-16 |
股东大会：
将于2021-05-20召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Friedman LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To consider and act upon a proposal to approve the Amended and Restated 2010 Equity Compensation Plan;
4.To consider and act upon a proposal to approve the Amended and Restated 2010 Directors’ Equity Compensation Plan;
5.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2020-04-16 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified (Proposal 1);
2.To ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2);
3.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2019-11-20 |
除权日：
美东时间 2019-12-02 每股派息0.25美元
|
| 2019-04-19 |
股东大会：
将于2019-05-22召开股东大会
会议内容 ▼▲
- 1.To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified (Proposal 1);
2.To ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019 (Proposal 2);
3.To hold an advisory vote to approve the compensation of our named executive officers (the “Say-on-Pay Vote”) (Proposal 3);
4.To hold an advisory vote on the frequency of future Say-on-Pay Votes (Proposal 4);
5.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2018-12-24 |
除权日：
美东时间 2019-01-09 每股派息0.25美元
|
| 2018-05-07 |
除权日：
美东时间 2018-06-06 每股派息1.00美元
|
| 2018-04-19 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- (1)To elect as directors the four nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
(2)To ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
(3)To consider and act upon a proposal to approve the Amended and Restated 2010 Equity Compensation Plan;
(4)To consider and act upon a proposal to approve the Amended and Restated 2010 Directors’ Equity Compensation Plan;
(5)To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2018-03-23 |
股东大会：
将于2018-04-12召开股东大会
会议内容 ▼▲
- 1.To approve the Company’s 2018 Stock Incentive Plan;
2.To approve the Amended and Restated 2015 Executive Employment Agreement with Ted Karkus, the Company’s Chairman and Chief Executive Officer.
|
| 2017-04-20 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1.To elect as directors the five nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements therof.
|
| 2017-03-03 |
股东大会：
将于2017-03-29召开股东大会
会议内容 ▼▲
- 1.To consider and act upon a proposal to sell substantially all of the assets of the Company, which are comprised of the intellectual property and other assets relating to its Cold-EEZE brand and product line, to Meda Consumer Healthcare Inc. (“MCH”), a Delaware corporation, and an affiliate of Mylan Inc. (together with MCH, “Mylan”), a Pennsylvania corporation, for cash, pursuant to that certain Asset Purchase Agreement, dated as of January 6, 2017, as amended, by and among the Company, MCH and Mylan Inc., and the other transactions contemplated thereby.
2.To consider and act upon a proposal to grant the persons named as proxies discretionary authority to vote to adjourn the special meeting, if necessary, to solicit additional proxies to vote in favor of Proposal No. 1.
3.To transact such other business as may properly come before the special meeting and any adjournment thereof.
|
| 2016-04-18 |
股东大会：
将于2016-05-24召开股东大会
会议内容 ▼▲
- (1)To elect as directors the nominees named in the proxy statement to serve as our board of directors for the ensuing year until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
(2)To consider and act upon a proposal to approve an amendment and restatement of our Amended and Restated 2010 Equity Compensation Plan to increase the number of shares issuable thereunder by seven hundred thousand (700,000) shares;
(3)To ratify the appointment of EisnerAmper LLP as independent auditors for the year ending December 31, 2016;
(4)To approve the advisory (non-binding) resolution regarding the compensation of our named executive officers;
(5)To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|